Webinars Presents:

Ebstein’s Anomaly and the ACHD Patient

Wednesday, 7/12/2017, 7 p.m. – 8 p.m. EDT

Presenter: Jonathan Ginns, MD

About the Webinar

Ebstein’s anomaly is a congenital heart defect in which the tricuspid valve develops too low in the right side of the heart, often resulting in leakage of the valve. It occurs in one out of every 200,000 people. It can affect children and adults with symptoms varying from mild to severe. Treatment depends on the severity of the valve leakage and symptoms. Have you, a friend or a family member ever been told you have Ebstein’s anomaly? Are you bothered by shortness of breath, low oxygen levels, leg swelling or palpitations caused by arrhythmias? Do you know the importance of seeing an adult congenital heart doctor? Do you want to learn more about the spectrum of Ebstein’s anomaly and what the treatment options are? If so, you don’t want to miss this webinar. Register today.

REGISTER NOW:
https://zoom.us/webinar/register/ebf0e469de25a82f8c34be5db4a05ad8

About the Presenter

Jonathan Ginns, MD, is an adult congenital heart disease cardiologist working at the Schneeweiss Adult Congenital Heart Disease unit at Columbia-New York Presbyterian Hospital. His interests include clinical cardiology and echocardiography; he also reads cardiac MRI and CT and performs diagnostic cardiac catheterizations.

About the Adult Congenital Heart Association

The Adult Congenital Heart Association (ACHA) is a national not-for-profit organization dedicated to improving the quality of life and extending the lives of adults with congenital heart disease (CHD). ACHA serves and supports the more than one million adults with CHD, their families and the medical community—working with them to address the unmet needs of the long-term survivors of congenital heart defects through education, outreach, advocacy, and promotion of ACHD research. For more information about ACHA, contact (888) 921-ACHA or visit www.achaheart.org.

This webinar is made possible in part by unrestricted educational grants from Actelion Pharmaceuticals US, Gilead Sciences, Inc., and St. Jude Medical Foundation.